NEW PERSPECTIVES OF THE ROLE OF LOCAL THERAPY IN METASTATIC SEMINOMA

Professor Robert Huddart - Professor of Urological Cancer / Institute of Cancer Research and Royal Marsden Hospital FT, London

Robert Huddart’s major research interests are in bladder and testicular cancer. In regard to testicular cancer his major interests are in the management of testicular cancer with a focus on improving outcomes in high-risk disease, minimising toxicity in low-risk disease, work on survivorships issues and the genetics of testicular cancer. He has served as Chair of the National Cancer Research Institute Testis CSG, had been chief investigator and co-investigator of a number of major UK/international protocols.

FEMALE GERM CELL CANCER

Dr. Michelle Lockley - Consultant Medical Oncologist / University College Hospital

Dr Lockley specialises in the treatment of ovarian cancer. She completed her PhD in oncolytic viral therapies in ovarian cancer at the Barts Cancer Institute (BCI), Queen Mary University of London and subsequently held a NIHR Clinical Lectureship at the University of Cambridge. Dr Lockley has held both a Clinician Scientist Fellowship and an Advanced Clinician Scientist Fellowship from Cancer Research UK. She leads a laboratory research team at BCI where she is Deputy Lead for the Centre for Cancer Cell and Molecular Biology and Reader in Medical Oncology. She practices clinically at University College London Hospital.

Dr Lockley’s research aims to discover new systemic treatments for ovarian cancer. Her lab is particularly interested in novel viral and immunotherapies as well as strategies to tackle treatment resistance including drug re-purposing and adaptive therapy. She has a clinical research interest in rare gynaecological cancers, particularly ovarian germ cell tumours and is a member of MaGIC, the malignant germ cell tumour international consortium. To support research into gynaecological malignancies, she set up and continues to lead the Barts/UCLH Gynae Tissue Bank, a repository of tissues and clinical data that are kindly donated by her patients.

TERATOMA DIFFERENTIATED AND SOMATIC MALIGNANT TRANSFORMATION

Professor Dan Berney - Consultant Urological and Endocrine Pathologist / St Bartholomew's Hospital London

Dan Berney is current working at Barts. He has been Secretary of the International Society of Urological Pathologists, Chairman of the British Society of Urological Pathologists and is currently Editor in Chief of the journal Histopathology. He has over 200 papers and was one of the architects of the revised WHO class-action of testicular tumours in 2015.

POTENTIAL CLINICAL UTILITY OF CIRCULATING MICRORNAS FOR TESTICULAR GERM CELL MALIGNANCY

Dr. Matt Murray - University Lecturer and Honorary Consultant Paediatric Oncologist Department of Pathology / University of Cambridge and Department of Paediatric Haematology and Oncology

University Lecturer and Honorary Consultant Paediatric Oncologist Department of Pathology, University of Cambridge and Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS FT monitoring and detection of relapse in this disease. Biology Co-Lead and Executive Committee Member of MaGIC (Malignant GCT International Collaborative) Member of NCRI TYA and Testis Cancer Clinical Studies Group

Matthew Murray has a particular interest in the clinical and molecular aspects of germ cell tumours (GCTs), and was the first to demonstrate the potential utility of specific circulating microRNAs for diagnosis, disease.

GERMLINE GENOMIC ARCHITECTURE OF TESTICULAR GERM CELL TUMOURS

Dr. Chey Loveday - Higher Scientific Officer / Institute of Cancer Research (ICR), London, UK.

Chey undertook his PhD in cancer genetics at the ICR between 2008-2012. He has a combined 10 years plus experience within the division of Genetics and Epidemiology at the ICR, straddling both wet lab and dry lab activities. His work, as part of a team, has led to the identification and characterisation of multiple novel and known genetic determinants of testicular, breast and ovarian cancer, including both common and rare susceptibility alleles. His current research aims include further delineation of the germline genomic architecture of susceptibility to various cancers through large-scale GWAS and whole exome sequencing studies.​

NHS SCOTLAND QUALITY PERFORMANCE INDICATORS (QPIS) FOR TESTIS CANCER

Dr. Jeff White - Consultant Medical Oncologist and Dr. Mark Baxter / Beatson West of Scotland Cancer Centre, Glasgow and University of Glasgow

Jeff White has been a consultant medical oncologist at the Beatson West of Scotland Cancer Centre since 2004, his tumour types are germ cell cancer and sarcoma, leading to an interest in TYA oncology. He particularly enjoys working in the multi professional teams associated with the management of these cancers. He is the principal investigator on a number of multi institutional phase 2&3 studies in these areas.

SOCIAL MEDIA, WHY ARE HEALTH CARE PROFESSIONALS SO SCARED?

Shievon Smith - Uro-Oncology Clinical Nurse Specialist. / St Bartholomew’s Hospital, London

Sheivon Smith has had a professional career in Nursing for 18 years; DipHE Nursing. Clinical background A&E. Changed to Urology then uro-oncology in a CNS training post at Broomfield Hospital. Completed Cancer BSc at the Royal Marsden. Currently working at St Barts as a CNS for Dr Shamash, Dr Alifrangis and Prof Powles. Special interests Bladder cancer and patient survivorship.

ADAPT PROJECT

Professor John Radford - Professor of Medical Oncology Division of Cancer Sciences / University of Manchester and The Christie Hospital NHS FT

John Radford has had a career long interest in Hodgkin and non-Hodgkin lymphoma. He currently leads the NIHR Manchester Patient Safety Translational Research Centre’s theme on the oncology tertiary care/primary care interface. John has a major interest in reducing late treatment toxicity especially in second cancers. He chairs the Centre for Living Beyond Cancer Science steering committee and is also leading several digital health projects. At the Christie Hospital John leads a busy clinical practice in lymphoma and has been Director of Research since 2007

BLEOMYCIN- FRIEND OR FOE?

Professor Colm Leonard - Consultant Clinical Adviser Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence / Manchester University Hospitals NHS Foundation Trust & Manchester Academic Health Sciences Centre

Colm Leonard is a Thoracic Physician with an interest in lung transplantation.

DEALING WITH DIAGNOSTIC UNCERTAINTY: MICROLITHIASIS AND SMALL TESTICULAR LESIONS

Mr Aziz Gulamhusein - Consultant Urological Surgeon / The Christie NHS Foundation Trust

Mr Gulamhusein has a specialist interest in testicular cancer, kidney cancer and sarcoma for which he performs complex open and robotic retroperitoneal surgery. He holds an honorary contract at The Royal Marsden Hospital in London and visits regularly for joint operations with the testicular cancer team.

Mr Gulamhusein graduated from Sheffield Medical School in 2008 and proceeded to complete his basic surgical training and urological training within the South Yorkshire. He subsequently undertook a prestigious Royal College of Surgeons (RCS) robotic kidney surgery fellowship at the Royal Free Hospital in London, the highest volume kidney surgery centre in Europe with >400 cases a year. Prior to undertaking his fellowship in London, he was awarded a RCS grant to visit a ERUS robotic host centre in Aalborg, Denmark.

He has a keen interest in medical education and was a previous lead for the urology module at the Sheffield Medical School. He has completed a Postgraduate Certificate in Medical Education and is on the faculty for various courses and educational programmes. His research interests include the use of novel technology to improve surgical outcomes as well as enhanced recovery from surgery.

REVIEW OF RECENT, ONGOING AND UPCOMING TRIALS

Professor Dan Stark - Professor of Teenage and Young Adult Cancer Research Consultant in Medical Oncology / Department of Oncology, Leeds Institute of Oncology, St James’s Hospital, Leeds

Dan Stark is a consultant in medical oncology who has led the regional germ cell practice across our network of around 5 million people from 2006 to 2020. He is the current chair of the NCRI Teenage and Young Adult and Germ Cell tumour Research group. He has a research portfolio including models of care for TYA, service innovation for germ cell tumours, and basic biology of germ cell tumours.

REVIEW OF RECENT KEY PUBLICATIONS IN FIELD OF GERM CELL / TESTIS CANCER

Dr Jonathan Shamash - Consultant Medical Oncologist / Honorary Senior Lecturer Department of Medical Oncology / St Bartholomew's Hospital London

Jonathan Shamash is a medical oncologist specializing in management of urological cancers in particular germ cell tumours. He is Chair the Germ Cell subgroup of the NCRI TYA/GCT National Clinical Study Group and has been responsible for developing clinical studies in testicular cancer. He is Chair the Anglian Germ Cell Network. The data collected by this group has been used in large scale collaborations. He is interested in the de-escalation of therapy for metastatic germ cell tumours – with the use of carboplatin monotherapy in metastatic seminoma and the development of non cisplatin based combination chemotherapy in the management of relapsed germ cell tumours.